Topic Compilations

Topic Compilations

Each of our Topic Compilations includes a collection of features and news articles published in ASH Clinical News related to a specific hematologic disorder.

FDA Expands Approval of Dasatinib for Pediatric Patients With CP-CML

The U.S. Food and Drug Administration expanded the indication of the tyrosine kinase inhibitor dasatinib to include pediatric patients with Philadelphia chromosome–positive (Ph+) chronic-phase...

FDA Approves Lower Dose of Rivaroxaban for Recurrent VTE

The U.S. Food and Drug Administration approved 10 mg once-daily dosing for rivaroxaban to prevent recurrent venous thromboembolism (VTE) after at least six months...

Patients With CLL Willing to Trade Treatment Efficacy for Reduced Costs and Adverse Events

Some patients living with chronic lymphocytic leukemia (CLL) are willing to accept drugs that are less effective in exchange for reduced adverse events (AEs)...

Anticoagulation During Pregnancy

Because of physiologic changes during pregnancy, the risk of venous thromboembolism (VTE) is approximately five to 10 times higher than during non-pregnancy, and the...

How I Treat in Brief: New Agents in Myeloma

This month, Philippe Moreau, MD, discusses the changing landscape of multiple myeloma (MM) therapeutics and options for treatment in frontline and relapsed settings. This material...

The Ins and Outs of Inclusion Criteria for Myeloma Clinical Trials

Clinical trial protocols often incorporate strict eligibility criteria to maximize reproducible, results with minimal risk to trial participants. Unfortunately, restricting a trial’s patient population...

How I Treat In Brief: Atypical Chronic Myeloid Leukemia

This month, Jason Gotlib, MD, discusses the diagnosis and treatment of patients with atypical chronic myeloid leukemia. This material was repurposed from “How I Treat...
WIB_icon

Selinexor Induces Response in Patients With Various Subtypes of Non-Hodgkin Lymphoma and Chronic Lymphocytic...

The heterogeneity of the various subtypes of non-Hodgkin lymphomas (NHLs) necessitates the development of specific therapies that address fundamental mechanisms that are dysregulated in...

Is MRD Testing Worthwhile in Myeloma?

With the clinically effective treatment regimens now available for myeloma, more patients can achieve deep and sustained responses. The ability to measure minimal residual...

BFORE Trial: Bosutinib Could Be a “Welcome” New Treatment Option for Chronic-Phase CML

Treatment with the dual SRC/ABL tyrosine kinase inhibitor bosutinib was associated with a higher major molecular response (MMR), deeper response, and shorter time to...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.